AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CSL312 (GARADACIMAB) IN THE PROPHYLACTIC TREATMENT OF HEREDITARY ANGIOEDEMA

Registry ID

CSL312_3002

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

CSL BEHRING

Start date

2021-06-17

Last update

2021-01-06

Conditions

• HEREDITARY ANGIOEDEMA

Related clinical trials

• PHASE 3 TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF NAVENIBART IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA – ORBIT-EXPANSE
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF SIRNA TARGETING OF PREKALLIKREIN WITH ADX-324 IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA
• POST STUDY ACCESS OF CSL312 (GARADACIMAB) FOR THE ROUTINE PREVENTION OF HAE ATTACKS IN PEDIATRIC PARTICIPANTS (2-11 YEARS OLD) WITH HEREDITARY ANGIOEDEMA (HAE) WHO HAVE COMPLETED CSL312_3003 STUDY
• PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NAVENIBART IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA ¿ ALPHA-ORBIT
• A PHASE 4 OPEN-LABEL STUDY TO EVALUATE THE SAFETY AFTER SWITCHING TO CSL312 (GARADACIMAB) FROM CURRENT PROPHYLACTIC HAE TREATMENT IN SUBJECTS WITH HAE ¿ 12 YEARS OF AGE
• HAELO: A PHASE 3, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NTLA-2002 IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA

View on source registry